[Form 4] ORACLE CORP Insider Trading Activity
Michael D. Sicilia, listed as Chief Executive Officer, reported the acquisition of a large stock option award in Oracle Corporation (ORCL). The Form 4 shows a derivative transaction dated 09/24/2025 in which 1,037,412 stock options were acquired with an exercise (conversion) price of $308.46. The filing reports the options as directly beneficially owned following the transaction.
The options have an exercisable/expiration date entry of 09/24/2035 and the form states that 25% of the shares subject to the option vest annually on each anniversary of the grant date. The form is signed by an attorney-in-fact, Aimee Weast, under power of attorney dated 06/12/2025, with signature dated 09/26/2025.
- Large, disclosed award: The filing explicitly reports acquisition of 1,037,412 stock options, providing transparency on executive compensation.
- Clear vesting schedule: The Form 4 states 25% vests annually, giving investors explicit timing of when options become exercisable.
- None.
Insights
TL;DR: CEO received a sizable long-dated option grant of 1,037,412 options at $308.46 with standard annual vesting.
The Form 4 documents a single reporting-person filing by Michael D. Sicilia showing acquisition (code A) of 1,037,412 stock options on 09/24/2025 at a stated conversion price of $308.46. The disclosure that 25% vests each anniversary indicates a four-year vesting schedule beginning at grant. The options are recorded as directly beneficially owned and have an exercisable/expiration date noted as 09/24/2035, implying a long option term as disclosed. The filing was executed via power of attorney, which is properly noted on the form.
TL;DR: A large option award was granted to the CEO with multi-year vesting and a $308.46 strike, consistent with executive compensation disclosures.
The reported derivative transaction shows acquisition of 1,037,412 options with a conversion price of $308.46 and annual 25% vesting, which is a common structure for executive equity incentives. The option details (amount, price, vesting cadence, and long dated exercisability entry) are explicitly stated on the Form 4 and permit stakeholders to model potential future dilution and cost when combined with company disclosures elsewhere.